Gene Information from Publications |
| Publication Link |
Summary of findings |
| 18223457 |
Observational study of genotype prevalence. (HuGE Navigator) |
| 18281305 |
Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 12207635 |
Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 12242601 |
Observational study of genotype prevalence. (HuGE Navigator) |
| 12439223 |
Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 12629583 |
Observational study of gene-disease association. (HuGE Navigator) |
| 14515060 |
Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 15178651 |
Observational study of genetic testing. (HuGE Navigator) |
| 15194512 |
Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 15248218 |
Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 15284537 |
Observational study of gene-disease association. (HuGE Navigator) |
| 15383491 |
Observational study of genotype prevalence. (HuGE Navigator) |
| 15622315 |
Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 15825040 |
Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 15864119 |
Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 16116487 |
Observational study of gene-disease association. (HuGE Navigator) |
| 16125881 |
Observational study of gene-disease association, gene-gene interaction, and gene-environment interaction. (HuGE Navigator) |
| 16183265 |
Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 16267764 |
Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) |
| 16338275 |
Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 16392089 |
Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 16433869 |
Observational study of gene-disease association. (HuGE Navigator) |
| 16506047 |
Observational study of genotype prevalence. (HuGE Navigator) |
| 16538176 |
Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 16772608 |
Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 16815693 |
Observational study of genotype prevalence. (HuGE Navigator) |
| 16912957 |
Observational study of gene-disease association. (HuGE Navigator) |
| 16951995 |
Observational study of genotype prevalence. (HuGE Navigator) |
| 17015050 |
Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 17047492 |
Clinical trial of gene-gene interaction, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 17178267 |
Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 17223085 |
Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 17235330 |
Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 17309129 |
Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 17329992 |
Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 17352764 |
Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 17356468 |
Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 17391322 |
Observational study of genotype prevalence. (HuGE Navigator) |
| 17407229 |
Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 17465455 |
Observational study of genotype prevalence. (HuGE Navigator) |
| 17502835 |
Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 17654295 |
Clinical trial of gene-gene interaction, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 17900275 |
Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 17918089 |
Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 18004205 |
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) |
| 18024866 |
Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 18057928 |
Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 18090046 |
Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 17559344 |
CYP2B6 polymorphism markedly influences the metabolism of efavirenz in human liver microsomes and represents a first step toward elucidating the mechanism by which this allele identifies patients exhibiting very high efavirenz plasma concentrations. |
| 18004205 |
CYP2B6 genetic variation is associated with the metabolism of nicotine and cotinine among individuals with decreased CYP2A6 activity |
| 17638512 |
With over 100 described single nucleotide polymorphisms, numerous complex haplotypes and distinct ethnic frequencies, CYP2B6 is one of the most polymorphic CYP genes in humans. |
| 17391322 |
Significant interethnic differences occur at the CYP2B6 locus, which may influence treatment outcomes with efavirenz. |
| 17682072 |
Results show that 2-phenyl-2-(1-piperidinyl)propane (PPP) is a selective chemical inactivator of CYP2B6 and be used to define the role of CYP2B6 in the metabolism of drugs. |
| 17885627 |
CYP2B6*29 represents a new mechanism of genetic variation at the CYP2B6 locus, underscoring the highly polymorphic nature of this isoenzyme. |
| 17356468 |
CYP2B6-G516T polymorphisms significantly affect the CL/F rate of EFV in children. |
| 17465455 |
Results document the spectrum of CYP2B6 allelic variants and genotypes in a southern Chinese population. The 516G > T allele is associated with a defective metabolism of efavirenz (EFV), which therefore may predispose to drug toxicity. |
| 15194512 |
Data show that the mean plasma efavirenz concentration of HIV-1 patients homozygous for CYP2B6 *6/*6 (Q172H and K262R) was significantly higher than that of patients heterozygous for *6 or without alleles *6. |
| 15864119 |
CYP2B6 polymorphism has a role in plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients |
| 12738724 |
Down-regulation of cytochrome P450 CYP2B6 is associated with breast cancer |
| 12490624 |
substitution of residue 363 in CYP2B6 resulted in significant alterations of the metabolite profile for the side chain hydroxylation of 7-butoxycoumarin |
| 17502835 |
single nucleotide polymorphisms in the promoter region or introns in the CYP2B6 affect the potency of cyclophosphamide activation to 4-hydroxycyclophosphamide |
| 12571232 |
a novel xenobiotic-responsive enhancer module in the distal region of the CYP2B6 promoter (CYP2B6-XREM) together with the PBREM mediates optimal drug-induced expression of CYP2B6 |
| 16495778 |
a novel specific CYP2B6 allele in Africans causes impaired metabolism of the HIV drug efavirenz |
| 16506047 |
CYP2B6 variants, previously shown to affect metabolism of a variety of drugs, occur in West Africa and Papua New Guinea, and there are significant genetic differences at the CYP2B6 locus in these populations |
| 17054410 |
the reliable and quick Pyrosequencing assay affords facilitated future research on the importance of CYP2B6 |
| 17455229 |
Decreased expression of CYP2B6 might play a role in the development of prostate cancer, and be useful as the prognostic predictor for human prostate cancer. |
| 15572372 |
AMPK has a role in the phenobarbital induction of CYP2B gene expression |
| 16338275 |
CYP2B6 genotype influences (S)-methadone and, to a lesser extent, (R)-methadone plasma levels. |
| 15563456 |
The two cis-acting elements, the distal PBREM and the proximal OARE, within the chromatin structure are both regulated by CAR in response to okadaic acid and TCPOBOP to maximally induce the CYP2B6 promoter. |
| 16623664 |
SMC1 binding represses OARE [OA (okadaic acid) response element] activity and its dissociation allows the recruitment of CAR(constitutive active/androstane receptor) to the OARE, synergizing the expression of the CYP2B6 gene. |
| 14977870 |
CYP2B6 is highly inducible by known CYP3A4 inducers and suggest that human pregnane X receptor is a major determinant of CYP2B6-inducible expression |
| 11991950 |
expression in hepatocytes by vitamin D receptor pathway |
